Adamas, Flexion sell for $825M combined as biotech’s dealmaking pace picks up
The two deals announced Monday are attempts by Supernus and Pacira to fold small, revenue-generating drugs into a larger portfolio and boost their prospects.
Supernu...
Continue Reading →
